Baxter reports Q3 2026 earnings beat, raises full‑year outlook and announces cephalosporin shutdown
Baxter International posted third‑quarter 2026 adjusted earnings of $0.58 per share, beating consensus by $0.06, and revenue of $2.98 billion, surpassing estimates. The company lifted its full‑year adjusted EPS guidance to a range of $2.05‑$2.15 and raised its organic sales growth outlook to 3%‑4%. In the earnings call, Baxter introduced new CFO John Rogers and said it will discontinue cephalosporin production at its Round Lake facility, a step tied to recent FDA warning‑letter concerns.
Why it matters
The earnings beat and higher guidance suggest stronger cash generation and may support further balance‑sheet strengthening, while the cephalosporin shutdown aims to simplify operations and address FDA compliance issues, potentially limiting future disruption. Analysts note the guidance lift could improve valuation models, but the FDA warning remains a risk factor.
Key facts
- 1Adjusted earnings per diluted share were $0.58, beating estimates by $0.06. seekingalpha.com
- 2Quarterly revenue was $2.98 billion, exceeding forecasts. seekingalpha.com
- 3Full‑year 2026 adjusted EPS guidance was raised to $2.05‑$2.15 per share. seekingalpha.com
- 4Organic sales growth outlook for 2026 was increased to 3%‑4% from 2%‑3%. finance.yahoo.com
- 5Baxter will discontinue production of cephalosporin products at its Round Lake facility. finance.yahoo.com
- 6The U.S. FDA issued a warning letter to Baxter on October 20, 2026 regarding the Round Lake plant. investing.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.